Zobrazeno 1 - 10
of 8 938
pro vyhledávání: ''
Autor:
Hiroyuki Motoyama, Norifumi Kawada, Kohei Kotani, Akihiro Tamori, Naoshi Odagiri, Hideki Fujii, Hoang Hai, Le Thi Thanh Thuy, Atsushi Hagihara, Minh Phuong Dong, Masaru Enomoto, Ritsuzo Kozuka, Etsushi Kawamura, Sawako Uchida-Kobayashi, Kanako Yoshida
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Scientific Reports
Scientific Reports
Soluble immune checkpoint molecules are emerging novel mediators of immune regulation. However, it is unclear whether soluble immune checkpoint proteins affect the development of hepatocellular carcinoma (HCC) during nucleos(t)ide analogue (NA) treat
Autor:
Tadashi Yoshino, Naoya Nakamura, Misa Sakamoto, Tomoka Ikeda, Yuria Egusa, Yoshito Nishimura, Yasuharu Sato, Azusa Fujita, Misato Doi, Noriko Iwaki, Asami Nishikori, Midori Filiz Nishimura, Yuka Gion
Publikováno v:
Cancer Medicine, Vol 11, Iss 2, Pp 417-432 (2022)
Cancer Medicine
Cancer Medicine
Background Most patients with methotrexate‐associated lymphoproliferative disorder (MTX‐LPD) show diffuse large B‐cell lymphoma (DLBCL) or classic Hodgkin lymphoma (CHL) types. Patients with MTX‐LPD often have spontaneous remission after MTX
Autor:
Fritz Offner, Karima Amaador, Kazem Nasserinejad, Dries Deeren, Efstathios Kastritis, Steven T. Pals, Willem Kraan, Jeanette K. Doorduijn, Roberto D Liu, Monique C. Minnema, Marcel Kap, Marie José Kersten, Lara H Böhmer, Lidwine W. Tick, Meletios A. Dimopoulos, Josephine M.I. Vos, Martine E D Chamuleau, Maria Gavriatopoulou
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(1), 40-51. American Society of Clinical Oncology
Kersten, M J, Amaador, K, Minnema, M C, Vos, J M I, Nasserinejad, K, Kap, M, Kastritis, E, Gavriatopoulou, M, Kraan, W, Chamuleau, M E D, Deeren, D, Tick, L W, Doorduijn, J K, Offner, F, Böhmer, L H, Liu, R D, Pals, S T & Dimopoulos, M A 2022, ' Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia : Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 1, pp. 40-51 . https://doi.org/10.1200/JCO.21.00105
Journal of clinical oncology, 40(1), 40-51. American Society of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(1), 40-51. American Society of Clinical Oncology
Kersten, M J, Amaador, K, Minnema, M C, Vos, J M I, Nasserinejad, K, Kap, M, Kastritis, E, Gavriatopoulou, M, Kraan, W, Chamuleau, M E D, Deeren, D, Tick, L W, Doorduijn, J K, Offner, F, Böhmer, L H, Liu, R D, Pals, S T & Dimopoulos, M A 2022, ' Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia : Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 1, pp. 40-51 . https://doi.org/10.1200/JCO.21.00105
Journal of clinical oncology, 40(1), 40-51. American Society of Clinical Oncology
PURPOSE Proteasome inhibitors are effective in Waldenström's macroglobulinemia (WM) but require parenteral administration and are associated with polyneuropathy. We investigated efficacy and toxicity of the less neurotoxic oral proteasome inhibitor
Autor:
Miguel Paja-Fano, Fernando Guerrero-Pérez, Juan J. Díez, Diana Ariadel Cobo, José Manuel Cabezas Agrícola, Javier Gavira, I. Peiró, Idoia Genua, Susan M. Webb, Manuel Mateu-Salat, Betina Biagetti, Pedro Iglesias, Antía Fernández Pombo, Mariona Riudavets, Carlos García Gómez, Carles Villabona, Cristina Lamas, Margarita Majem
Publikováno v:
ENDOCRINE-RELATED CANCER
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Central adrenal insufficiency (AI) due to isolated adrenocorticotropic hormone (ACTH) deficiency (IAD) has been recently associated with immune checkpoint inhibitor (ICI) therapy. Our aim was to analyze the prevalence, clinical characteristics, and t
Autor:
Yoshiaki Murakami, Shingo Seo, Hiroyuki Otsuka, Yasushi Hashimoto, Naru Kondo, Shinya Takahashi, Takeshi Sudo, Kenjiro Okada, Tatsuaki Sumiyoshi, Kenichiro Uemura
Publikováno v:
European Journal of Cancer. 159:215-223
Background The prognosis of patients with borderline resectable pancreatic cancer with arterial contact (BRPC-A) is extremely poor, and effective preoperative treatment is indispensable. We evaluated the clinical efficacy and safety of neoadjuvant ch
Autor:
Blanca Polo, Maria Joao Costa, Ana Vagos Mata, C. Lopes, João F. Lacerda, Daniela Alves, Eduardo Espada, João Raposo
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 24, Pp 8768-8776 (2021)
Cancer Medicine, Vol 10, Iss 24, Pp 8768-8776 (2021)
High‐dose methylprednisolone plus rituximab (R‐HDMP) is a useful treatment in chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) patients unfit for chemo‐immunotherapy and has proven its utility on the treatment of CLL/SLL compl
Publikováno v:
Leuk Lymphoma
Relapsed/refractory Primary Central Nervous System Lymphoma (R/R PCNSL) has a poor prognosis with no established preferred treatment. We report the efficacy and toxicity of a combination chemotherapy regimen: methotrexate, carmustine, etoposide, and
Autor:
Masahiko Mori, Takayuki Nagasawa, Takayuki Enomoto, Toru Sugiyama, Yuki Inokuchi, Satoru Nagase, Shoji Kamiura, Tetsuro Oishi, Shinichi Komiyama, Tadahiro Shoji, Masakazu Abe, Nobuhiro Takeshima, Aikou Okamoto
Publikováno v:
Cancer Science
We investigated the efficacy and safety of further bevacizumab therapy in patients with platinum‐resistant ovarian cancer whose disease had progressed after bevacizumab plus chemotherapy. In this multicenter, open‐label, phase II trial (JGOG3023)
Autor:
In Gyu Hwang, Sang-Cheol Lee, Yaewon Yang, Sung Yong Oh, Sang-Gon Park, So Yeon Jeon, Dae Young Zang, Jung Hun Kang, Jun Ho Ji, Hyun Woo Lee, Woo Kyun Bae, Sun Jin Sym, Se-Il Go, Joung Soon Jang, Jung Hoon Kim
Publikováno v:
European Journal of Cancer. 157:21-30
Background The efficacy of modified FOLFIRINOX (mFOLFIRINOX) as a second-line chemotherapy treatment for metastatic pancreatic adenocarcinoma (mPAC), remains unclear. This multi-center randomised phase III trial aimed to elucidate the efficacy of mFO
Autor:
Shogo Teraoka, Atsushi Takenaka, Katsuya Hikita, Masashi Honda, Hideto Iwamoto, Shuichi Morizane, Bunya Kawamoto, Noriya Yamaguchi, Tetsuya Yumioka, Ryutaro Shimizu
Publikováno v:
Anticancer Research. 41:5767-5773
BACKGROUND This study aimed to investigate the response to platinum-based chemotherapy rechallenge in patients with pembrolizumab-refractory urothelial carcinoma. PATIENTS AND METHODS We retrospectively reviewed 14 patients with pembrolizumab-refract